Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT04917302

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

Led by China Medical University Hospital · Updated on 2025-02-19

60

Participants Needed

1

Research Sites

320 weeks

Total Duration

On this page

Sponsors

C

China Medical University Hospital

Lead Sponsor

M

Ministry of Science and Technology, Taiwan

Collaborating Sponsor

AI-Summary

What this Trial Is About

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.

CONDITIONS

Official Title

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a DSM-5 diagnosis of schizophrenia
  • Are resistant to adequate treatments of at least two antipsychotics
  • Remain symptomatic without clinically significant fluctuation, with unchanged antipsychotic doses for at least 3 months and during the 12-week trial
  • PANSS total score 270
  • Agree to participate in the study and provide informed consent
Not Eligible

You will not qualify if you...

  • DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) that may interfere with the study
  • Clinically significant abnormal laboratory screening tests (including blood routine, biochemical tests)
  • Pregnancy or lactation
  • Inability to follow protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

Actively Recruiting

Loading map...

Research Team

H

Hsien-Yuan Lane, M.D., Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia | DecenTrialz